Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Cell International"
DOI: 10.1186/s12935-020-01614-z
Abstract: Venetoclax has been approved by the United States Food and Drug Administration since 2016 as a monotherapy for treating patients with relapsed/refractory chronic lymphocytic leukemia having 17p deletion. It has led to a breakthrough in… read more here.
Keywords: venetoclax; overcome resistance; hematologic malignancies; resistance ... See more keywords